How many clinical trials are studying Depemokimab?

6 recruiting trials in our tracked data involve Depemokimab.

What conditions is Depemokimab being studied for?

In our tracked recruiting trials, Depemokimab is being studied in trials for Asthma, COPD, Pulmonary Disease, Chronic Obstructive.

Depemokimab: clinical trials recruiting now

Q: Is Depemokimab FDA-approved?

Yes. According to the FDA drug label available through openFDA, Depemokimab is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Depemokimab appears in the FDA drug-label database. Marketed as Exdensur.

FDA-approved use

EXDENSUR is indicated for the add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. Limitations of Use EXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions ( 5.2 )] . EXDENSUR is an interleukin‑5 (IL‑5) antagonist, a monoclonal antibody (humanized immunoglobulin G1 [IgG1] kappa) indicated for add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. ( 1 ) Limitations of Use : Not for relief of acute bronchospasm or status asthmaticus. ( 1 )

FDA label via openFDA

Phase breakdown

Phase 3 6

Conditions being studied

Condition	Trials
Asthma · Depemokimab for Asthma	3
COPD · Depemokimab for COPD	3
Pulmonary Disease, Chronic Obstructive · Depemokimab for Pulmonary Disease, Chronic Obstructive	3

Recruiting trials involving Depemokimab

A Study of Depemokimab in Participants of 6 to 11 Years of Age
NCT07671001 · Phase: Phase 3 · Ages: 6 Years to 11 Years · Sex: All (male and female) · 3 locations
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 17 locations
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 50 locations
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
NCT06959095 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 15 locations
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 159 locations
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339 · Phase: Phase 3 · Ages: 40 Years to 75 Years · Sex: All (male and female) · 121 locations

Common questions

Is Depemokimab FDA-approved?

Yes, marketed as Exdensur.

How many recruiting trials involve Depemokimab?

6 recruiting trials across 3 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.